The Latest Breaking News from Moderna

The main Covid-19 booster offers good protection for at least three months.

Biotech firm’s data shows stronger immune response to Omicron than original vaccine three months after being given

Everybody over 50 is invited for a winter coronavirus jab but not everybody will get the new dual/bivalent vaccines that target multiple strains

Moderna Inc. will provide as many as 100 million doses of COVID-19 shots that specifically target variants for vaccine alliance Gavi to distribute in lower-income countries in 2023.

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Moderna Inc has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world's poorest people. The biotech company and vaccine alliance GAVI will cancel their existing supply deal for vaccines based on the original coronavirus strain. Instead, Moderna will supply up…

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

Manufacturers Moderna and Merck are testing a breakthrough cancer vaccine for patients suffering from melanoma which kills thousands of people each year in the UK

The major indexes tumbled to bear market lows after a hot CPI inflation report, but then roared back. Earnings season is getting underway.

While Western donors have stumped up significant funding for a programme to make Covid-19 vaccines in Africa, activists say more support is needed to help poor countries secure the intellectual property rights they need to produce mRNA vaccines beyond the pandemic.

"This study is too flawed to be used to set policy on the mRNA vaccines in younger males," one expert said